Asymmetric dimethylarginine in obesity after renal transplantation.
OBJECTIVE
We have assessed in obese renal transplant recipients a course of selected proinflammatory factors liable to influence the long-term outcome of transplant patients and kidney grafts.


METHODS
In a prospective cohort study, we examined a total of 68 obese renal transplant recipients (body mass index [BMI] >or= 30 kg/m(2)) for a period of 12 months (Group I). A control group consisted of 72 comparable non-obese renal transplant recipients (Group II).


RESULTS
Significant differences were found in plasma 12 months after renal transplantation (Group I versus Group II) in asymmetric dimethylarginine (ADMA; 3.68 micromol/L +/- 0.42 micromol/L vs 2.10 micromol/L +/- 0.34 micromol/L; P < .01), adiponectin (ADPN; 15.1 microg/mL +/- 6.0 microg/mL vs 22.80 microg/mL +/- 7.2 microg/mL; P < .01), leptin (50.4 ng/L +/- 10.2 ng/L vs 22.0 ng/L +/- 8.4 ng/L; P < .01), solubile leptin receptor (ObRe; 23.6 U/mL +/- 7.4 U/mL vs 47.2 U/mL +/- 10.7 U/mL; P < .01), resistin (21.2 microg/mL +/- 10.2 microg/mL vs 15.0 microg/mL +/- 6.2 microg/mL; P < .025) and triglycerides (3.9 mmol/L +/- 1.6 mmol/L vs 2.8 mmol/L +/- 1.6 mmol/L; P < .01). There were significant correlations between ADMA and BMI (r = 0.525, P < .001), ADPN and BMI (r = -0.574, P < .001), and ADMA and ADPN in visceral fat (r = -0.510, P < .001). Correlation between ADMA and Cin was weak, but significant (r = -0.190, P < .05).


CONCLUSIONS
The results indicate that obesity after renal transplantation was associated with increased plasma ADMA and decreased ADPN in plasma and in fat tissue and may represent a risk factor for renal transplant recipients.
Teplan
Vladimir
V
Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine and Postgraduate Medical School, Prague, Czech Republic. vladimir.teplan@medicon.cz
Schück
Otto
O
Racek
Jaroslav
J
Lecian
Dalibor
D
Haluzik
Martin
M
Kudla
Michal
M
Vitko
Stefan
S
D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000368:Aged; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D015992:Body Mass Index; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000502:physiology; D020738:Leptin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000503:physiopathology; D011446:Prospective Studies; D054411:Receptors, Leptin / Q000097:blood; D052243:Resistin / Q000097:blood; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D052242:Adiponectin; D020738:Leptin; D054411:Receptors, Leptin; D052243:Resistin; D014280:Triglycerides; C487735:dimethylarginine; D001120:Arginine